Several research groups have reported that patients with breast cancer with abundant TILs showed good survival outcomes and good chemotherapy responses, especially the patients with triple-negative breast cancer (TNBC) and human epidermal growth factor receptor-2 (HER2)-positive breast cancer [3–5]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.